Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantation

Clin Immunol. 2019 Aug:205:49-56. doi: 10.1016/j.clim.2019.05.010. Epub 2019 May 18.

Abstract

Mycophenolate mofetil (MMF) is an immunosuppressive agent that is widely used in graft-versus-host disease prophylaxis because of its inhibitory function on T cells and B cells. However, the effect of MMF on natural killer cell reconstitution after allogenic hematological transplantation is largely unknown. The present study examined the effects of different MMF administration durations after haploidentical allo-HSCT on NK cell reconstitution. Ninety patients were enrolled in this study and defined into two groups in term of MMF duration. We found that MMF patients in the long-term MMF group were associated with a poor reconstitution of NK cells and a significantly lower cytotoxicity from day 30 to day 180 post-transplantation. Especially, the long-term MMF group inhibits reconstitution of NKp30 NK subsets, which correlated with higher risk of EBV viremia. Multivariate analysis showed that a better reconstitution of NKp30 cells was associated with lower EBV viremia (HR0.957, p = .04). In vitro experiments demonstrated that the active metabolite of MMF, mycophenolic acid (MPA), inhibited the proliferation and cytotoxicity of NK cells from healthy donors or patients at day 30 post-transplantation. In summary, our findings demonstrated that long-term MMF administration delayed the quality and quantity of NK cells, especially NKp30 subpopulations, which was associated with decreased EBV viremia post allogeneic HSCT.

Keywords: Allo-HSCT; MMF; NK cells; NKp30; Reconstitution.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Duration of Therapy
  • Epstein-Barr Virus Infections / epidemiology*
  • Female
  • Graft vs Host Disease / prevention & control*
  • Hematopoietic Stem Cell Transplantation*
  • Herpesvirus 4, Human
  • Humans
  • Immune Reconstitution / immunology*
  • Immunosuppressive Agents / administration & dosage*
  • Immunosuppressive Agents / therapeutic use
  • Killer Cells, Natural / immunology*
  • Killer Cells, Natural / metabolism
  • Leukemia, Myeloid, Acute / therapy
  • Male
  • Middle Aged
  • Mycophenolic Acid / administration & dosage*
  • Mycophenolic Acid / therapeutic use
  • Myelodysplastic Syndromes / therapy
  • Natural Cytotoxicity Triggering Receptor 3 / metabolism
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Proportional Hazards Models
  • Transplantation, Homologous
  • Viremia / epidemiology*
  • Young Adult

Substances

  • Immunosuppressive Agents
  • NCR3 protein, human
  • Natural Cytotoxicity Triggering Receptor 3
  • Mycophenolic Acid